Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on June 19, 2020, covering events occurring on June 18, 2020. The Company is a Delaware corporation headquartered in San Diego, California, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The Board of Directors increased the size of the Board from seven to eight directors. Concurrently, Dr. Mark Erlander, the Company's Chief Executive Officer, was appointed as a director, effective immediately.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Confirm the effective date of Dr. Mark Erlander's appointment to the Board of Directors.
- Verify the updated total number of directors on the Board (now eight).
- Review the Company's most recent 10-Q or 10-K for financial performance data not included in this 8-K.